CD79A and COVID-19: In 159 symptomatic patients with COVID-19 from North America, the median time to seroconversion to SARS-CoV-2 RBD was, on average, 4 days earlier for hospitalized patients compared with non-hospitalized patients over all isotypes (IgG, IgM, and IgA), suggesting an association between antibody kinetics and disease severity (90).